Live | Norge | Sverige | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDX | FondForsinkede kurser. Sist oppdatert: fredag 20. oktober
Oversikt
Kursliste
Indekser
Nyheter
Største handler
Meglerandel
Tegningsretter
Historikk
Vinnere/tapere
Høy/lav
Dato Antall dager Distributør Papir Børs Søk  
Dato Tid Selskap Overskrift
19/10-2017 08:00:21 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:21 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:00 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (Cision)
18/10-2017 08:31:00 BGBIO God rekruttering av pasienter (Hegnar)
  08:00:27 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:26 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:00 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
  08:00:00 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
Sidestørrelse:

Utforming  |   Hjelp  |   Utskrift
Lokal tid i Norge: 20/10-2017 07:06:35. Ingen åpne markeder